Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines
Patrizia Carpinelli, Alessia Montagnoli(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Riccardo Colombo(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Helena Posteri(Nerviano Medical Sciences), Giulia Canevari(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Eduard Felder, Stefania Re Depaolini(Nerviano Medical Sciences), Marisa Montemartini, Walter Ceccarelli(Nerviano Medical Sciences), Sabrina Cribioli(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Maria Gabriella Brasca(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury
|Cell Death and Disease|2015|129